Presentation is loading. Please wait.

Presentation is loading. Please wait.

CDER / CBER Pharmacovigilance Working Group

Published byCameron Willis Modified over 8 years ago

Similar presentations

Presentation on theme: "CDER / CBER Pharmacovigilance Working Group"— Presentation transcript:

1 CDER / CBER Pharmacovigilance Working Group
Risk Assessment of Observational Data: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment CDER / CBER Pharmacovigilance Working Group

2 Working Group Members Group Leads: Julie Beitz Mark Goldberger
Jeff Siegel Bette Goldman Jerry Davis Roselie Bright Mary Beth Jacobs Support: Aileen Ciampa Jane Axelrad Virginia Beakes Nichelle Cherry Jane McCarthy Kathy Miracco Yi Tsong Edward Cox Dan Shames Susan Lu Joyce Weaver Marianne Mann Judy Staffa Carol Holquist Min Chen Melodi McNeil Ralph Schmid Group Leads: Julie Beitz Mark Goldberger Miles Braun Project Manager: Patrick Guinn

3 Workshop Agenda Morning Afternoon Overview
Good Pharmacovigilance Practices Presentations, Qs and As Afternoon Pharmacoepidemiologic Assessment Closing Remarks

4 Scope of Concept Paper Present FDA’s preliminary thoughts on:
Important pharmacovigilance concepts Safety signal identification Pharmacoepidemiologic assessment and interpretation of safety signals The development of pharmacovigilance plans

5 Scope of Concept Paper Focus on risk assessment based on observational data sources Case Reports, Case Series Pharmacoepidemiologic Studies Registries Surveys

6 What is Pharmacovigilance?
All post-approval scientific and data gathering activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other product- related problems This includes the use of pharmacoepidemiologic studies

7 Pharmacovigilance: Why?
At the time of approval, clinical trial data are available on limited numbers of patients treated for relatively short periods Once a product is marketed, large numbers of patients may be exposed, including: Patients with co-morbid illnesses Patients using concomitant medications Patients with chronic exposure

8 Pharmacovigilance: Why?
After marketing, new safety information may become available: Through use of the product domestically or in other countries Through use of other drugs in the same class From preclinical studies From pharmacologic studies From controlled clinical trials

9 What is a Safety Signal? An apparent excess of adverse events associated with use of a product Even a single well-documented case report may be viewed as a signal

10 What is a Safety Signal? Preclinical findings or experience with other products in the class may be sufficient to generate a signal, even in the absence of case reports in patients A product’s risk profile may be characterized by several safety signals

11 Safety Signals Are identified Are evaluated Are interpreted
From case reports, other sources Are evaluated In pharmacoepidemiologic studies, registries, surveys Are interpreted In the context of all available safety information Are monitored Through enhanced pharmacovigilance efforts

12 What is a Pharmacovigilance Plan?
A plan proposed by a sponsor for the ongoing evaluation of safety signals identified with the use of a product to monitor at-risk populations which have not been adequately studied Plan may be developed at the time of product launch or after a signal is identified

13 What is a Pharmacovigilance Plan?
A sponsor’s plan may involve: Expedited reporting of serious adverse events of interest Submission of adverse event report summaries at more frequent, pre-specified intervals Conduct of additional observational studies or clinical trials Implementation of active surveillance activities to identify as yet unreported adverse events

14 Active Surveillance May Involve...
Product-based activities Follow cohorts of patients exposed to specific products Setting-based activities Surveillance of healthcare settings (e.g., EDs) for events likely to present there Event-based activities Monitor registries for events that are often drug-related (e.g., liver transplant registries)

15 Emerging new safety data may result in ongoing revisions to the sponsor’s pharmacovigilance plan for a product

16 While additional safety information is being developed, FDA will work with sponsors to:
communicate information about safety signals and minimize events occurring in users of a product through risk management programs1 1Concept Paper: Risk Management Programs

17 Workshop Agenda Morning Afternoon Overview
Good Pharmacovigilance Practices Presentations, Qs and As Afternoon Pharmacoepidemiologic Assessment Closing Remarks

Download ppt "CDER / CBER Pharmacovigilance Working Group"

Similar presentations

Mary Ellen Turner MD, MPH Vice-President

Mary Ellen Turner MD, MPH Vice-President
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.

Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
Susan Boynton, VP, Global Regulatory Affairs, Shire

Susan Boynton, VP, Global Regulatory Affairs, Shire
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.

1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
06/05/2015 Risk Management Plan 24. April 2008 Helge Gydesen Epidemiology Novo Nordisk A/S.

06/05/2015 Risk Management Plan 24. April 2008 Helge Gydesen Epidemiology Novo Nordisk A/S.
Assessing the Safety of Marketed Drugs Current Issues and Controversies Captain Paul J. Seligman, M.D., MPH Associate Director, Safety Policy and Communication.

Assessing the Safety of Marketed Drugs Current Issues and Controversies Captain Paul J. Seligman, M.D., MPH Associate Director, Safety Policy and Communication.
Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.

Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.

1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
Patient Safety Initiatives Kelly Cronin Director, Patient Safety and Outcomes Research Office of Policy and Planning Office of the Commissioner FDA.

Patient Safety Initiatives Kelly Cronin Director, Patient Safety and Outcomes Research Office of Policy and Planning Office of the Commissioner FDA.
JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.

JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.

IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.

DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.

 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Introduction Russell Ellison, MD Chief Medical Officer Vice President, Medical Affairs.

Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Introduction Russell Ellison, MD Chief Medical Officer Vice President, Medical Affairs.
The Food and Drug Administration Amendments Act of 2007: Implications of the Drug Safety Provisions Carolyn D. Jones, J.D., MPh Director, Regulatory Policy.

The Food and Drug Administration Amendments Act of 2007: Implications of the Drug Safety Provisions Carolyn D. Jones, J.D., MPh Director, Regulatory Policy.
1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.

1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.

Similar presentations

Ads by Google